The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaLise Willems, Jérôme Tamburini, Sylvie M. Guichard et al.|Leukemia|2011Cited by 161
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous SchedulesSylvie M. Guichard, Sabina Cosulich|Molecular Cancer Therapeutics|2015Cited by 125
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Chad J. Creighton et al.|Breast Cancer Research|2014Cited by 70
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast CancerMaureen Caligiuri, Sylvie M. Guichard|Targeted Oncology|2023Cited by 30